On the stock market since 2003, it operates in the everyday-essentials business. It has 4,100 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 26% a year over the last 4 years. Every year shown ended in profit.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 21% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 26% a year on average.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
It pays out $0.16 per share each year — regular cash for whoever holds the stock.
The company’s market value is 35 times its annual profit. Even a small disappointment could hit the price hard.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 27/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 39/100.
On our five-subject report card, UTI sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: UTI is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.